Table 2.

 Reasons for premature discontinuation of the study

Reason for premature discontinuation*	EcN (n = 162)	Mesalazine (n = 165)
Deterioration of disease (relapse not included)	1 (0.6%)	1 (0.6%)
Newly emerged exclusion criterion during study	4 (2.5%)	2 (1.2%)
Patient’s request	13 (8.0%)	9 (5.5%)
Adverse events	3 (1.9%)	6 (3.6%)
Insufficient patient compliance	6 (3.7%)	6 (3.6%)
Insufficient patient cooperation (diary)	6 (3.7%)	3 (1.8%)
Patient did not appear anymore	2 (1.2%)	5 (3.0%)
Other reasons	1 (0.6%)	2 (1.2%)
Patients with premature discontinuation	19 (11.7%)	20 (12.1%)

*Multiple reasons possible.

EcN, Escherichia coli Nissle 1917.